Results 211 to 220 of about 5,255,551 (319)

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

Molecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal   +16 more
wiley   +1 more source

Multi-gradient permutation survival analysis identifies mitosis and immune signatures steadily associated with cancer patient prognosis. [PDF]

Elife
Cai X, Ye Y, Liu X, Fang Z, Chen L, Li F, Ji H.   +6 more
europepmc   +1 more source

Genes and gene regulation

The Journal of Physical Fitness and Sports Medicine, 2021
openaire   +2 more sources

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Editorial: The role of genes and network pharmacology in new drug discovery

Frontiers in Genetics
Jingxin Mao, Jingxin Mao
doaj   +1 more source

A cost-effectiveness analysis model of actionable genomic alteration testing strategies incorporating different modalities and sizes of next-generation sequencing panels in non-small-cell lung cancer. [PDF]

Ther Adv Med Oncol
Ang YLE, Ong JCM, Huang Y, Low JL, Sooi K, Nützinger J, Wang XJ, Gibbs M, Goh BC, Soo RA.   +9 more
europepmc   +1 more source

Epigenomics: maternal high‐fat diet exposure in utero disrupts peripheral circadian gene expression in nonhuman primates

, 2010
Melissa Suter, Philip Bocock, Lori Showalter, Min Hu, Cynthia Shope, Robert A. McKnight, Kevin L. Grove, Robert H. Lane, Kjersti Aagaard‐Tillery   +8 more
openalex   +2 more sources

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

SF3B1K700E mutation in human embryonic stem cells causes aberrant expression of immune-related genes. [PDF]

PLoS One
Dastpak M, Mimoso CA, Farshchian M, Paraggio CL, Leonard CE, Yin S, Chi B, Nassar KW, Rowe RG, Zhang J, Hou Z, Daley GQ, Adelman K, Reed R.   +13 more
europepmc   +1 more source